AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04902820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEPTECH website
Description: The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and a mail-order pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine \[200 mg\]/tenofovir disoproxil fumarate \[300 mg\]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
Study NCT04902820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online PrEP resource list
Description: Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
Study NCT06422702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosomatic Symptoms Intervention
Description: Psychosomatic symptoms included intervention of negative psychological symptoms and intervention of physical discomfort symptoms.
Study NCT06422702 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Extended supportive care
Description: The control group implemented continuity of supportive care based on primary care
Study NCT05072184 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ESP block
Description: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
Study NCT05072184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
Study NCT05238064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib.~Maintain treatment: 2.5mg orally every day continuously, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years.
Study NCT05238064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide: 750mg/m2, IV, d1 Doxorubicin: 50mg/m2, IV, d1 Vincristine: 1.4mg/m2, IV, d1 (maximum 2mg) Prednison: 100mg, po, d1-5 21 days per cycle
Study NCT06279572 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06279572 — intervention group
Intervention type: PROCEDURE
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate
Study NCT06279572 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study NCT06539507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX17725
Description: BCX17725 for injection
Study NCT04770246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-117
Description: TAS-117 will be dosed orally every day on a 21-day cycle
Study NCT04770246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-117
Description: TAS-117 will be dosed intermittently on a 21-day cycle
Study NCT04770246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-117
Description: TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
Study NCT05634083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Uremic pateints with itching
Description: Activated charcoal
Study NCT06287827 — intervention group
Intervention type: PROCEDURE
Intervention: Simplified protocol
Description: MUAC-based dosing:~* SAM \[MUAC \<115mm or WHZ \<-3 or oedema (+/++)\] = Two 92g sachets Ready to use Therapeutic Food (RUTF)/day (Approx. 1000 kcal/day).~* MAM \[MUAC 115mm\<125mm or WHZ \<-2\] = One 92g sachet RUTF/day (Approx. 500 kcal/day).
Study NCT06287827 — intervention group
Intervention type: PROCEDURE
Intervention: Standard protocol
Description: Weight-based dosing~* SAM: Mid-upper-arm circumference (MUAC) \<115mm or Weight-Height/length Z Score \<-3 or mild or moderate bipedal oedema: 150-185 kcal/kg/day is offered using RUTF until the patient passes to MAM and then the dose is reduced to 100 -130 kcal/kg/day using RUTF until recovery.~* MAM: MUAC 115-\<125mm or Weight-Height/length Z Score \<-2: 100-130 kcal/kg/day is offered using RUTF until recovery.
Study NCT05310786 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)
Description: This is not a true intervention, but rather a clinical model of care established at an FQHC in Maine.
Study NCT05405361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-117
Description: Intravenous administration of ARGX-117
Study NCT05405361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration of placebo
Study NCT05859009 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-Guided Therapy of Glue and Coil
Description: This clinical trial aims to evaluate the effectiveness and safety of endoscopic ultrasound (EUS)-guided therapy of glue and coil in the management of gastrointestinal bleeding due to varices. The procedure involves the insertion of a catheter through an endoscope to deliver glue and/or coils to the bleeding site, under EUS guidance. Patients who meet the inclusion criteria will undergo EUS-guided therapy of glue and coil, followed by follow-up assessments to evaluate the outcomes of the procedure, including bleeding recurrence and adverse events.
Study NCT05859009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Selective Beta Blockers (Propanolol)
Description: Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
Study NCT05958147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-PRF
Description: thorough scaling and root planing is performed followed by withdraw of 5ml of blood from antecubital vein of patient with consent . Following C-PRF protocol of 3000rpm for 8 min centrifugation is performed. 1ml of plasma is drawn from the test tube just above the red blood cell layer and allowed to clot and the formed clot is placed in the periodontal pocket after scaling and root planing
Study NCT06127524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEM Scanner
Description: Implementation of the SEM Scanner as part of weekly standard skin assessments of sacrum and heels
Study NCT04525014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: RRx-001 will be administered every 3 weeks via intravenous infusion at three dose levels: 0.5 mg/m2 (Max 1 mg), 1 mg/m2 (Max 2 mg), and 2 mg/m2 (Max 4 mg).
Study NCT04525014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100 mg/m2 (children ≥0.5 m2) or 3 mg/kg (children \<0.5 m2) daily for 5 days beginning on day 1 of each cycle
Study NCT04525014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 90 mg/m2 taken orally daily for 5 days administered 1 hour after temozolomide
Study NCT06539507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for injection
Study NCT05741905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
Study NCT05741905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levofloxacin simulant
Description: Levofloxacin simulant is placebo. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
Study NCT05813067 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: JDS-HF 3.0
Description: Take 2 capsules once daily in the mornings with food
Study NCT05813067 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 2 capsules once daily in the mornings with food
Study NCT04930237 — intervention group
Intervention type: DRUG
Intervention: Relistor Injectable Product
Description: 12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days
Study NCT04930237 — intervention group
Intervention type: DRUG
Intervention: Docusate Calcium
Description: Standard of care
Study NCT04930237 — intervention group
Intervention type: DRUG
Intervention: Bisacodyl
Description: Standard of Care
Study NCT04930237 — intervention group
Intervention type: DRUG
Intervention: Milk of magnesia
Description: Standard of Care
Study NCT04930237 — intervention group
Intervention type: DRUG
Intervention: Magnesium citrate
Description: Standard of Care
Study NCT04930237 — intervention group
Intervention type: DRUG
Intervention: Senna
Description: Standard of Care
Study NCT04930237 — intervention group
Intervention type: DRUG
Intervention: Enema
Description: Standard of Care
Study NCT05188755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetric test during submaximal exercise
Description: * metabolic evaluation by indirect calorimetry at rest and during exercise~* evaluation of cardiac output~* peripheral quantitative computed tomography (pQCT) of the muscle cross section~* evaluation of body composition~* assessment of physical capacity (chair test and 3 min step-test)~* blood test~* assess the level of physical activity
Study NCT05188755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect calorimetric test during submaximal exercise
Description: * metabolic evaluation by indirect calorimetry at rest and during exercise~* evaluation of cardiac output~* peripheral quantitative computed tomography (pQCT) of the muscle cross section~* evaluation of body composition~* assessment of physical capacity (chair test and 3 min step-test)~* blood test~* assess the level of physical activity
Study NCT04549311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic 1 arm (amoxicillin + clavulanic acid)
Description: Prescription of antibiotics (amoxicillin + clavulanic acid) after incision and drainage of perianal abscess.
Study NCT04549311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic 2 arm (ciprofloxacin + metronidazole)
Description: Prescription of antibiotics (ciprofloxacin + metronidazole) after incision and drainage of perianal abscess.
Study NCT04591977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV Self-Sampling Kit (Evalyn Brush)
Description: The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
Study NCT06624904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 50mg
Description: Single dose losartan (50 mg), encapsulated identically to placebo.
Study NCT06624904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single tablet encapsulated identically to placebo.
Study NCT06325137 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptome analyses
Description: A sample of peripheral whole blood cells will be collected at the onset before the initiation of steroid treatment (time 0, t0) and after 6 weeks at the definition of steroid sensitivity/unresponsiveness (time 1, t1).
Study NCT06178783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Brensocatib oral solutions will be expectorated following the tasting.
Study NCT05225298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Offering SARS-CoV-2 test
Description: A pragmatic cluster (facility-level) randomized clinical trial, comparing test-based screening performed at a static (every two weeks) frequency versus a dynamic frequency (ranging from once a week to once every four weeks) anchored to county COVID-19 case rates
Study NCT03484936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
Study NCT03484936 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.
Study NCT05046379 — intervention group
Intervention type: OTHER
Intervention: Lipidomics
Description: Lipidomics is the large-scale study of lipids (fats and fat-like molecules) within biological systems. It involves identifying and quantifying the wide variety of lipids in cells, tissues, or organisms to understand their roles in metabolism, signaling, and disease. Lipidomics is a subfield of metabolomics and uses advanced analytical techniques, like mass spectrometry, to profile lipid molecules. It helps in studying how lipids contribute to cellular functions, disease development, and responses to therapies.
Study NCT06163742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Product X
Description: The investigational device is a polyethylene glycol-based biomaterial. It can be applied to donor sites on the arms, torso, and legs.
Study NCT06163742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care
Description: The active comparator includes the current standard-of-care treatment: hydrocellular polyurethane dressing covered with TegadermTM film for 48 hours, followed by an occlusive gauze impregnated with 3% Bismuth Tribromorphenate in petrolatum.
Study NCT05180721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of patient portal for diabetes management
Description: A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
Study NCT06089408 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Use a regular blanket
Study NCT06089408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Use a weighted blanket
Study NCT05040022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoperitoneum pressure 10 mmHg
Description: The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10)
Study NCT05040022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pneumoperitoneum pressure 14 mmHg
Description: The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14).
Study NCT05065190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Description: nintedanib
Study NCT05065190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05763953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil NS
Description: Part 1A: At least 12 patients will be administered with Etripamil NS (35 mg/100 μL per nostril) at a dose of 70 mg.~Part 1B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 1A.~Part 2A: At least 12 patients will be administered with Etripamil NS at a dose selected based on appropriate body size-based modeling using PK assessments, as well as safety/tolerability, and efficacy data collected in Part 1.~Part 2B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 2A.
Study NCT06089408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06089408 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05762614 — intervention group
Intervention type: OTHER
Intervention: Dyspnea assessment
Description: Dyspnea assessment, respiratory variability, Spirometry, Electromyography
Study NCT05624866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
Study NCT05624866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
Study NCT05434143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chorus Sleep
Description: During the 6-week intervention, participants will receive daily reminders to complete their daily sleep log and a link to a chorus sleep class for them to listen to that night.~The daily sleep class involve listening to 15 minute audio sessions, which include guided mediation and breathing exercises.
Study NCT05496972 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey Administration
Description: Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine
Study NCT04719403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealthPAL
Description: Participants who are randomly assigned to the HealthPAL arm will have immediate post- visit access to audio/video-recordings of their clinical visit through a HIPAA-compliant web-based program called HealthPAL.
Study NCT06307119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy and Relaxation Group
Description: MOHO Based Intervention~The client-centered occupational therapy comprises five distinct stages:~1. Client-Centered Goal Setting:It involves collaboratively establishing goals the client's needs and aspirations.~2. Creating the Therapy Plan:Comprehensive therapy plan is devised from the findings from OSA and MOHOST results.~3. Implementing the Interventions:These interventions aimed addressing various personal challenges,financial management,stress management.~4. Evaluating the Results:It involves adjusting the therapy plan as needed based on the participant's responses and outcomes.~5. Receiving Feedback~Jacobson's Progressive Muscle Relaxation~Starting with the lower extremities,participants sequentially tensed and relaxed muscle groups,moving from distal to proximal regions,encompassing toes,ankles,thighs,buttocks,abdomen,fingers,triceps,shoulders,and face.During all these stages,it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds.
Study NCT06307119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Group
Description: Jacobson's Progressive Muscle Relaxation (JPMR) Participants underwent training in relaxation techniques involving mental visualization and Jacobson's progressive muscle relaxation method with the aid of music. Starting with the lower extremities, participants sequentially tensed and relaxed muscle groups, moving from distal to proximal regions, encompassing toes, ankles, thighs, buttocks, abdomen, fingers, triceps, shoulders, cervical muscles, and face. During all these stages, it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds.
Study NCT04988425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNFα Monoclonal Antibody
Description: Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
Study NCT04988425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Injection of 500mg of methylprednisolone immediately after admission before surgery.
Study NCT04988425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection of the same volume of saline immediately after admission before surgery
Study NCT05765084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination
Description: WT1/DC vaccines (8-10 x 10\^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered on day 14 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Additional WT1/DC vaccinations after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week).
Study NCT05765084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (1200 mg) will be administered on day 0 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Atezolizumab should be administered before chemotherapy administration as an IV infusion over 60 (±15) minutes. If the first infusion is tolerated, all subsequent infusions may bedelivered over 30 (±10) minutes. Additional atezolizumab treatment (1680 mg) after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week) as an IV infusion over 30-60 minutes.